



21 December 2021

Australian Securities Exchange Announcement

Data licensing

Total Brain Limited (“Total Brain,” or “TTB”) a digital mental health SaaS company advises the market that the Company has entered a perpetual, non-exclusive license with Janssen Research & Development, LLC for its iSPOT-D (International Study to Predict Optimized Treatment for Depression) research data, effective immediately.

Total Brain will receive a one-off license fee of USD \$2.2M within 90 days. The license is subject to conventional commercial termination provisions.

Authorised on behalf of the Total Brain board of directors by Non-Executive Director Matt Morgan.

For further queries, please contact:

Investor

Simon Poidevin

President – Australia & New Zealand

E: simon.poidevin@totalbrain.com

Media

Nigel Kassulke

Managing Director, Teneo Consulting

E: nigel.kassulke@teneo.com

M: +61 (0) 407 904 874

About Total Brain Limited (ASX: TTB)

Total Brain Limited is a San Francisco and Sydney-based company that has developed and offers Total Brain, a mental health monitoring and support platform powered by the world’s largest standardized brain database. Its SaaS platform has helped more than 1 million registered users to-date scientifically measure and optimize their brain capacities while managing the risk of common mental conditions. Benefits for employers and payers include better mental healthcare access, lower costs and higher productivity. Benefits for providers include improved patient outcomes, tracking of evidence-based outcomes across the continuum of care, and a reduction in clinician fatigue. For more information, please visit www.totalbrain.com and follow us on [Twitter](#), [LinkedIn](#) and [Facebook](#).